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ABSTRACT
Features like small size, low refractive index and polydispersity pose challenges to the currently
available detection methods for Extracellular Vesicles (EVs). In addition, the lack of appropriate
standards to set up the experimental conditions makes it difficult to compare analyses obtained
by different technical approaches. By modifying synthetic nanovesicles with recombinant anti-
genic regions of EV-enriched tetraspanins, we aimed to construct an EV-mimetic that can be used
as a suitable standard for EV analyses.
To this end, the sequences of the large extracellular loops of the tetraspanins CD9, CD63 and CD81
were tagged with a target sequence for the biotin ligase BirA, and co-transformed with a BirA
expression plasmid into Escherichia coli. GST fusion proteins were then isolated by affinity chromato-
graphy and released using thrombin. Biotinylated recombinant tetraspanin-loops were then coupled
to (strept)avidin-coated synthetic nanovesicles and analysed and characterised by Dot-blot, Western-
blot, Nanoparticle Tracking Analysis, Flow Cytometry and Transmission Electron Microscopy.
With this method, we were able to efficiently produce tetraspanin-domain decorated nano-
vesicles that share biophysical properties with natural EVs, can be detected using specific
antibodies against common EV markers such as tetraspanins, and can be used as robust reference
materials for detection techniques that are often used in the EV field.
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Introduction
Extracellular Vesicles (EVs) are released by most cell
types, either by fusion of multivesicular bodies with the
plasma membrane at the end of the endocytic recycling
pathway (usually named exosomes), or by direct bud-
ding form the plasma membrane (commonly called
microvesicles or ectosomes) [1]. EVs are emerging as
a potent mechanism of intercellular communication
because of their ability to act as a vehicle for the
exchange of genetic and protein material between
cells [1]. In the last two decades, EVs have become
the focus of many studies because of their putative
use as non-invasive biomarkers and their potential in
bioengineering and clinical applications [2]. However,
current quantitative and qualitative detection methods
for EVs are hindered by intrinsic features of EVs, such
as small size, low refractive index and polydispersity.
These factors together with the lack of well-
characterised and reproducible Reference Materials
(RM) make it difficult to compare results between
samples and different laboratories [3,4].
We therefore aimed to design an Extracellular
Vesicle-Mimetic (EVMs) based on the use of niosomes
as a scaffold of self-assembled nanovesicles. This strat-
egy can thus be considered either a fully synthetic-
bottom-up EV, or a semi-synthetic artificial EV with
surface modifications following a classification recently
proposed [5]. Niosomes are obtained by hydration of
non-ionic surface-active agents with appropriate
amounts of cholesterol and other amphiphilic mole-
cules [6]. Niosomes, similarly to liposomes, display
a bilayer structure, nanometric scale size, a refractive
index comparable to that of EVs [7,8]. Additionally,
niosomes can be modified through bioconjugation pro-
cesses with proteins and fluorescent dyes [5].
Furthermore, niosomes have lower production costs
and are stable for longer periods of time when
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compared to liposomes, two characteristics of special
importance for a RM development [6,9]. The use of
synthetic rather natural EVs can offer advantages like
a higher and more controllable production yield
important for scale-up applications [10].
The tetraspanins CD9, CD63 and CD81 are among the
most abundant membrane proteins on natural EVs and
are routinely used as markers for their characterisation.
Within the tetraspanin protein structure, the large extra-
cellular loop (LEL) is the most antigenic region, and is
where the majority of available anti-tetraspanin antibo-
dies bind [11,12]. Since the production of recombinant
transmembrane domains is highly complex, we took the
alternative approach of using only the immunogenic LEL
domain of the tetraspanins for the construction of the
EVMs. In addition, we decided to take advantage of the
high-affinity interaction between (strept)avidin–biotin
molecules to decorate the surface of the niosomes with
these recombinant large extracellular tetraspanin loops.
This strategy shows that these nanovesicles can serve as
adaptable EVMs and can be successfully used as a novel
RM for EV research. They can be isolated and purified by
various EV-isolation methods and analysed on multiple
platforms used within the EV research field, including
Nanoparticle Tracking Analysis (NTA), Electron
Microscopy (EM) and Flow Cytometry (FC).
Materials and methods
Antibodies
Primary antibodies anti-CD9 (clones VJ 1/10 and VJ1/
20), anti-CD63 (clones TEA 3/10 and TEA 3/18 and
H5C6), anti-CD81 (clone Eat2) mAbs have been pre-
viously described [13] and were purchased from
Immunostep or BD Bioscience either unconjugated or
as PE-conjugates. Anti-CD81 (clone 5A6) mAb was
kindly provided by Dr Shoshana Levy (Stanford, USA).
Synthetic nanovesicles
Commercially available niosomes (Nio-N-GF-MAL) were
purchased from Nanovex Biotechnologies (Asturias,
Spain). According to the manufacturer’s description,
these niosomes are composed of a formulation of lipids
and non-ionic surfactants (Span 60 (Sorbitane monostea-
rate), Tween 60 (Polyoxyethylenesorbitan monolaurate),
Cholesterol and DSPE-2000-MAL (1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[maleimide(polyethy-
lene glycol)-2000] (ammonium salt)) with the following
molar ratios: 0.5:0.5:1:0.01) that were hydrated with 2 mL
PBS 20 mM pH 7 at 60°C. To generate fluorescent
niosomes, 1,2 dioleoyl-sn-glycerol phosphoethanolamine
modified with carboxyfluorescein molecules was included
in the formulation. The mixture is then shaken for two
minutes and sonicated using a bath sonicator for 15min to
produce nanovesicles with a size range between 50 and
300 nm.
Surface modification of niosomes was also performed
by Nanovex Biotechnologies. The bioconjugation with
streptavidin (SA) or avidin was performed through thiol
activated groups within the molecules of the bilayer,
thereby generating a covalent bond between (strept)avidin
molecules and the niosomes. One milligram of
a sulfhydryl-containing protein (SA or avidin) was dis-
solved in a 4 mL niosome solution and incubated for 2
h after previous deprotection of the reactive groups of the
SATA activated strept(avidin) with hydroxylamine-HCL.
To remove residual hydroxylamine and deacylation pro-
ducts, samples were desalted by gel filtration using
Sephadex G-75. The bioconjugated niosomes were puri-
fied using a column of Agarose 6%. The amount of
unbound (strep)avidin was measured by a Bradford assay
in the filtrated fraction. Final niosome solutions were
analysed using Dynamic Light Scattering (DLS) and
NTA to determine their size and concentration, respec-
tively. The change in the Z potential of the bioconjugated
niosomes confirmed the presence of (strep)avidin on the
surface of niosomes. In the niosome stocks used in the
manuscript the amount of (strept)avidin conjugated to the
surface was reported to be 232 μg/mL of avidin in the
fluorescent niosomes and 224 μg/mL of SA in non-
fluorescent niosomes.
Construction of recombinant biotinylated
tetraspanin LEL expression plasmids
AviCD9LELAvi, AviCD63LELAvi and AviCD81LELAvi
sequences were cloned into the pGEX-4T2 expression
vector. DNAs sequences corresponding to the LEL of
CD9, CD63 and CD81 tetraspanins were amplified by
PCR using master mix solution 2X (Promega), 100 ng of
template DNA (CD9-, CD63- or CD81-GFP) constructs
[14,15] and the primers (Table 1) that included the
recognition sequences for BirA and restriction sites for
XhoI and BamHI. Products of PCR amplification were
inserted in the TOPO® TA vector (Invitrogen) and
transformed into supercompetent bacteria by heat
shock. Ampicillin-resistant clones were expanded and
sequenced. Validated clones were digested with XhoI
and BamHI and ligated in the reading frame of GST in
the final vector pGEX-4T2. Products of ligation were
verified by restriction pattern with XhoI and BamHI.
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Expression and purification of recombinant
tetraspanins
Protease-deficient supercompetent Escherichia coli BL21
cells were co-transformed with AviCD9 LELAvi-pGEX
-4T2, AviCD63 LELAvi-pGEX-4T2 or AviCD81 LELAvi-
pGEX-4T2 constructs together with a pBirAcm, an engi-
neered pACYC184 plasmid with an IPTG inducible BirA
gene to over-express the biotin ligase (isolated from the
K12 E. coli strain AVB99, Avidity LLC). Colonies were
selected and grown overnight in 50 mL of Luria-Bertani
(LB) medium containing 0.1 mg/mL ampicillin (Normon)
and 0.1mg/mL chloramphenicol (Sigma). The seed culture
was then transferred into 200mL of fresh LBmediumwith
antibiotics and the indicated concentration of D-Biotin
(Thermo Scientific) and cultured for 3 h at 37°C and
200 rpm. Isopropyl-beta-D-thiogalactopyranoside (IPTG,
Sigma) was then added to a final concentration of 0.3 mM
and bacterial culture continued for 2 h at 37°C and
200 rpm.
Cells were harvested by centrifugation at 4700 g for
15 min at 4°C. The bacterial pellet was resuspended in
10 mL of the indicated lysis buffers (Table 2), supplemen-
ted with protease inhibitors cocktail (Roche) and sonicated
as indicated. Bacterial lysates were centrifuged at 18,000 g
for 30 min at 4°C. Supernatant was collected and GST
fusion proteins were purified by affinity chromatography
using glutathione-sepharose 4B (GE Healthcare). Proteins
were cleaved and eluted from GST using site specific
protease thrombin (GE Healthcare). Benzamidine-
sepharose (Sigma-Aldrich) was used for the removal of
thrombin as previously described in detail [16]. Protein
concentration of the preparations was measured with
Micro BCA Protein Assay Kit (Pierce Company) following
the manufacturer’s instructions.
Samples along the purification process were boiled in
Laemmli buffer and resolved by 10% or 12% SDS-PAGE.
Gels were incubated with Coomassie Brilliant Blue for
5 min, followed by de-stain solution for 10 min.
For generation of non-biotinylated CD9LEL similar
procedures were followed using CD9EC2-GST con-
struct [15].
Western blot and dot blot analysis
For western blot analysis, samples were loaded onto
10% or 12% polyacrylamide gels.
Where indicated, AviCD9LELAvi, as well as a CD9LEL
constructs that were not taggedwith the Avi sequence were
produced and 6 μL of each recombinant peptide was
incubated with SA (Nanovex Biotechnologies) for 15 min
at RT using two different ratios (3-fold molar excess and
10-foldmolar excess of SA/tetraspanin LEL). Samples were
boiled in Laemmli buffer and resolved in a polyacrylamide
gel. After electrophoresis, the proteins were transferred to
a PVDF membrane (Biorad).
Table 1. Oligonucleotides used for PCR amplification of different human tetraspanin LELs. The restriction sites for XhoI (green) and
BamHI (blue), as well as the recognition sites for the biotin ligase enzyme or AviTag (red) were inserted at N- and C-terminus during
the PCR amplification.
Table 2. Different cell lysis conditions used in the optimisation of the production of recombinant tetraspanin LELs.
Number Lysis conditions used in cell lysis optimisation
1 Addition of 1% triton and 70% amplitude sonication of 5 pulses of 10 s each pulse with pauses of 10 s between pulses.
2 Incubation of suspension samples with lysozyme (10 mg/mL) and DNase I (1 µg/mL) during 1 h at 4°C followed by 10% sarkosyl and 70%
amplitude sonication of 5 pulses of 10 s each with pauses of 10 s between pulses.
3 Incubation of suspension samples with lysozyme (10 mg/mL) and DNase I (1 µg/mL) during 1 h at 4°C followed by 70% amplitude sonication of
5 pulses of 10 s each with pauses of 10 s between pulses.
4 Addition of 1% triton + 0,1% SDS and 70% amplitude sonication of 5 pulses of 10 s each with pauses of 10 s between pulses.
5 Incubation of suspension samples with lysozyme (10 mg/mL) and DNase I (1 µg/mL) during 1 h at 4°C followed by 10% sarkosyl + 0,1% SDS and
70% amplitude sonication of 5 pulses of 10 s each with pauses of 10 s between pulses.
6 Addition of lysozyme (10 mg/mL) and DNase I (1 µg/mL) and 0,1% SDS to the suspension of samples, followed by 70% amplitude sonication of
5 pulses of 10 s each with pauses of 10 s between pulses.
7 Incubation of suspension samples with lysozyme (10 mg/mL) and DNase I (1ug/mL) during 1 h at 4°C followed by 20% sarkosyl and 70%
amplitude sonication of 7 pulses of 10 s each with pauses of 10 s between pulses.
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For dot blot analysis, samples were spotted onto
a 0.22 μm pore size nitrocellulose membrane (GE
Healthcare) and let to dry.
Membranes were subsequently blocked with 5% non-
fat dry milk and blotted with ABC Peroxidase Standard
Staining Kit (Thermo Fisher Scientific) for 30 min at RT
or incubated overnight with primary antibodies at 4°C in
a humidified chamber. After washing, membranes were
probed with secondary antibody anti-mouse horseradish
peroxidase (Thermo Fisher Scientific) and Enhanced che-
miluminescent (ECL) HRP substrate (Thermo Scientific).
Chemiluminescence signal was detected using the
LAS4000 mini Image System analyser from Fujifilm and
software ImageQuant-TL (GE Healthcare).
Immunofluorescent analysis
100 μL of biotinylated CD9, CD63 and CD81 LELs
were incubated with 5 μL of SA-sepharose beads (GE
Healthcare) for 30 min. Primary antibodies against the
three different tetraspanins (hybridoma supernatants)
were added and incubated overnight at 4°C. Next,
samples were washed three times with TBS-T and
incubated for 30 min at 4°C with an AlexaFluor 488
goat anti-mouse IgG secondary antibody (Invitrogen).
Samples were washed three times with TBS-T and
mounted on coverslips with fluoromount (Thermo
Fisher). Confocal images were obtained with a Leica
TCS-SP5 confocal scanning laser microscope and Leica
confocal LAS software.
Coupling of recombinant tetraspanins to
nanovesicles
CD9, CD63 and CD81 biotinylated recombinant tetra-
spanin-LEL were incubated with (strept)avidin-coupled
niosomes. Incubation of recombinant tetraspanins and
nanovesicles was performed ON in a tube rotator at
RT. Unbound LEL peptide was removed by Size
Exclusion Chromatography (SEC). Sepharose CL-2B
(GE Healthcare) was stacked in a 1 mL syringe (BD,
Plastipak) and equilibrated using 0.22 μm filtered PBS,
thereby allowing the Sepharose to reach a final matrix
length of 6 cm at a diameter of 0.75 cm. Gravity elution
was next performed and 20 sequential fractions of two
drops (approximately 100 μL) were collected for each
sample.
Natural EVs
Human breast carcinoma cell-derived EVs were iso-
lated by SEC from conditioned media of MCF7 cell
cultures as described previously [17]. Mouse dendritic-
cell derived EVs were isolated from conditioned cell
culture medium by differential ultracentrifugation as
detailed in [18].
Nanoparticle tracking analysis (NTA)
Size distribution and concentration of nanovesicles was
determined by measuring the rate of Brownian motion
using a NanoSight LM10 system (Malvern) equipped
with 405 nm laser. For each sample, at least two videos
of 30 s were recorded and analysed with a detection
threshold 10. Data was obtained using a shutter speed
of 345 and a camera gain of 1.00. The measurements
were performed and monitored at ambient tempera-
ture. Recorded videos were analysed with NTA
Software version 2.2. Samples were diluted in PBS
until particle concentration was within the dynamic
range of NTA Software.
Electron microscopy (EM)
For cryo-EM, niosome samples were directly adsorbed
onto glow-discharged holey carbon grids
(QUANTIFOIL). For vitrification, grids were blotted
at 95% humidity and rapidly plunged into liquid
ethane with VITROBOT (Maastricht Instruments BV).
For immuno-EM, samples were fixed in 2% paraf-
ormaldehyde in PBS and deposited onto Formvar/car-
bon-coated EM grids, previously pre-coated with Poly-
L-lysine (MW of 15,000–30,000 kDa, Sigma Aldrich) as
described before [19]. The niosome-coated grids were
washed with PBS and finally blocked with PBS/1% BSA
for 15 min. Blocked grids were transferred to a drop of
PBS/0.1% BSA containing primary antibody and incu-
bated ON at 4°C in a humidified chamber. The grids
were washed on a drop of PBS, transferred to a drop of
PBS/0.1% BSA containing secondary antibodies conju-
gated to 15 nm gold-particles (Aurion) and incubated
for 2 h at RT in a humidified chamber. Grids were
washed with dH2O and fixed with 1% glutaraldehyde,
washed with H2O and stained with 2% uranyl acetate
for 1 min at RT. Afterwards, samples were vitrified as
described above and visualised using a JEM-2200FS
Field Emission TEM equipped with a digital camera
(JEOL).
Bead-assisted flow cytometry
Bead-assisted bulk FC analysis of niosome or EV sam-
ples was performed as previously described [17].
Briefly, samples were incubated with aldehyde/sul-
phate-latex beads (4 µm from Invitrogen) and sequen-
tially incubated with primary antibodies (hybridoma
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supernatants) and secondary anti-mouse IgG conju-
gated to Alexa 647 (Life Technologies). Samples were
analysed using a FACS Canto II (Becton Dickinson)
and FlowJo software (version X Tree Star).
High-resolution flow cytometry
For immunocharacterisation of decorated niosomes,
samples were incubated for 1 h at RT with phycoery-
thrin (PE)-conjugated monoclonal antibodies.
Antibodies used were: anti-CD9PE (clone VJ 1/20,
Immunostep) and anti-CD63PE (Clone H5C6, BD
Bioscience) at concentrations suggested by the manu-
facturer. Sucrose density gradient were used for the
removal of free unbound dye [20]. Briefly, bottom-up
density gradient floatation was performed by mixing
samples with 1.5 mL 2.5 M sucrose. Samples were next
overlaid in SW40 tubes (Beckman-Coulter) with fifteen
700 μL sucrose fractions of decreasing molarity (2.0 M
until 0.4 M). Gradients were then subjected to ultra-
centrifugation for 16 h at 200,000g (SW40 rotor; 4°C;
39,000 rpm; RCF average 192,072g; RCF max 270,519g;
κ-factor 144.5). Twelve fractions of 1 mL were collected
from which the density was determined by refractome-
try using an Atago Illuminator (Japan). Prior to acqui-
sition, sucrose samples were diluted 20 times in PBS.
As described previously, qualitative and quantitative
analysis of niosome-containing samples was then per-
formed using a jet-in-air-based BD Influx™ flow cyt-
ometer (Becton Dickinson) optimised for the detection
of submicron-sized particles [20,21]. Data obtained was
analysed using FlowJo Software version X.
Statistical analysis
Data analysis was performed using GraphPad Prism
version 6.0 (GraphPad Software Inc). Error bars repre-
sent the standard deviation (SD).
Results and discussion
Production of recombinant avilelavi proteins
For the production of recombinant human tetraspanin
LEL domains we chose three members that are widely
employed in EV research, namely CD9, CD63 and
CD81. Sequences corresponding to their LELs were
amplified by PCR. The 15 aminoacid sequence of the
AviTag peptide, that allows recognition and site-
specific biotinylation by the highly specific E. coli bio-
tin ligase A enzyme (BirA) [16], was then introduced at
both N- and C-term ends (Table 1) together with
restriction sites for subcloning into pGEX-4T2 vector
in reading frame with the glutathione-S-transferase
(GST). The plasmids coding for the Avi-tagged LEL
of either CD9, CD63 or CD81 (AviCD9 LELAvi-pGEX
-4T2, AviCD63 LELAvi-pGEX-4T2 or AviCD81
LELAvi-pGEX-4T2) were co-transformed into E. coli
(BL21 DE3) cells, together with a plasmid encoding
for BirA enzyme. Cells were grown and selected in
the presence of antibiotics (ampicillin and chloramphe-
nicol). Cultures were supplemented with D-Biotin and
IPTG, to induce both GST and biotinylation.
Bacterial lysis was optimised by testing six different
conditions (Table 2). These supernatants were affinity-
purified with glutathione-sepharose and analysed by SDS-
PAGE andCoomassie Blue staining (Figure 1(a,b)). Fusion
protein recovery was greatly improved by increasing
Sarkosyl concentration to 20% (lysis condition 7 in
Table 2; Figure 1(c)). To determine biotin concentration
for maximal biotinylation of the recombinant tetraspanin,
AviCD63LELAvi transformed E. coli were cultured in the
presence of different concentrations of D-biotin. Total
bacterial lysates were analysed by dot-blot to assess recom-
binant tetraspanin production, as well as biotinylation.
When normalised to the total load of protein detected
with anti-CD63 mAb, we found that biotinylation effi-
ciency (as detectedwithABCPeroxidase) slightly increased
with 20 µMof biotinwhen compared to the 5 µMcondition
(ratio of ABC signal/anti-CD63 signal was 1.4 when 5 µM
was set to 1). 20 µM of D-biotin was the concentration of
choice for all further experiments, since no major differ-
ences were observed when the biotin concentration was
increased to either 75 µM (ratio of 1.5) or 200 µM (ratio of
1.3) (Figure 1(d)).
Purification of the biotinylated GST fusion recombi-
nant LEL-tetraspanins was then performed by affinity
chromatography. First, the highly specific interaction
between GST and glutathione was employed to capture
proteins of interest on sepharose beads. In a second step,
proteins were cleaved and eluted fromGST using the site-
specific protease thrombin. Next, thrombin was removed
using benzamidine-sepharose beads (Figure 2(a)). Each
sequential step of the production of the recombinant
AviLELAvi peptides was evaluated by SDS-PAGE analy-
sis and Coomassie Blue staining. These analyses clearly
showed that the recombinant GST-LEL is greatly
enriched after affinity purification with glutathione-
sepharose beads (bands at 37 kDa in lanes 1–3 and 2–4,
respectively (Figure 2(b,c)). Cleavage with thrombin was
complete, as only the 23 kDa band of GST could be
detected in lanes 5–7 (Figure 2(b)). Because the cleaved
tetraspanin-LELs are difficult to detect by Coomassie
Blue staining due to their small size (a faint band can be
appreciated for CD9LEL in lane 8, red arrow in Figure 2
(b)), Western Blot analyses were used to confirm both the
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biotinylation and purity of the final recombinant CD9,
CD63 and CD81 products (Figure 2(c)). The molecular
weight detected for these peptides corresponds to the
12–15 kDa expected for the LEL of tetraspanins plus the
two AviTags (Figure 2(c), red arrows, lanes 5–7).
Dot Blot analysis, performed using tetraspanin spe-
cific monoclonal antibodies or the Avidin-Biotin HRP
Complex (ABC Peroxidase), showed strong positive
reactions, indicating that the recombinant LEL-
tetraspanins were biotinylated and maintained
immunogenicity by proper folding (Figure 2(d)).
Within the final product, MicroBCA assays revealed
a higher yield for CD9 and CD81 (112.3 ± 16.4 and
106.2 ± 14.3 μg/mL) recombinant peptides than for
CD63 (53.8 ± 14.8 μg/mL mean ± SD from five inde-
pendent determinations). Since the LEL of CD63 con-
tains two sites for N-glycosylation, the absence of this
post-translational modification may be affecting the
protein stability and final yield, although it does not
seem to impair antibody recognition.
Figure 1. Optimisation of the purification process of the recombinant biotinylated tetraspanin-LEL peptides. (a) Cell lysis optimisa-
tion. Six different lysis conditions (indicated in Table 2) were tested. 10 µL of the obtained AviCD63LELAvi-GST coupled to
Glutathione-sepharose beads were lysed in Laemmli buffer, subjected to SDS-PAGE and analysed by Coomassie Blue staining. (b)
Efficiency of recombinant protein recovery. Non-soluble fraction of the bacterial lysates obtained with lysis condition 2, as well as the
recombinant affinity purified AviLELAvi-GST proteins, were tested by SDS-PAGE to check the recovery of GST fusion proteins from E.
coli. Lanes 1–3: Bacterial lysates. Lanes 8–10: 10 µL of LELs-GST-Glutathione-sepharose. (c) Final optimisation of lysis conditions. Total
bacterial lysates obtained using condition 7, as well as the recombinant affinity purified AviLELAvi-GST proteins were analysed by
SDS-PAGE. Lanes 1,2,4: Non-soluble bacterial lysates. Lanes 7–9: 10 µL of LELs-GST-Glutathione-sepharose obtained. Red arrows
indicate the expected molecular weight for the recombinant fusion tetraspanins, which is 37 kDa. (d) Optimisation of D-biotin
labelling. Dot Blot analysis using an ABC Peroxidase Standard Kit and anti-CD63 specific antibody (clone TEA 3/10) for detection of
the indicated volumes of bacterial cell lysates from AviCD63LELAvi-GST-transformed cultures grown in the presence of the indicated
biotin concentrations.
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To assess the degree of biotinylation of the recom-
binant tetraspanin LELs, we produced and purified
AviCD9LELAvi, as well as an untagged CD9LEL pro-
tein. Recombinant LELs were incubated with SA and
analysed by Western blot using an anti-CD9 antibody
(Figure 3(a)). When the Avi-tagged biotinylated CD9
LEL was incubated with SA, the majority of CD9 signal
was found at higher molecular weights (Figure 3(a),
lanes 3–4), due to the binding of one or two LEL
peptides to the 52.8 kDa SA molecule. As expected,
no binding between SA and the untagged CD9LEL
could be observed (Figure 3(a), lanes 5–6), proving
that the interaction between the tetraspanin LEL and
SA molecules was mediated by biotin. Different
amounts of SA (3-fold molar and 10-fold molar excess)
were tested but showed no improved binding of
CD9LEL to SA (Figure 3(a), lane 4). However, a small
amount of Avi-tagged LEL peptide remained unbound
(Figure 3(a), lanes 3–4), suggesting that, although
highly efficient, complete biotinylation was not
achieved. Interestingly, the signal of the SA-bound
recombinant peptide was much stronger when com-
pared to the signal obtained when only the soluble
peptide was analysed (Figure 3(a), lane 2). This sug-
gests that, even though the soluble peptide can be
recognised by the CD9 antibody, the recognition is
greatly enhanced upon binding to SA. Since the LEL
domain is biotinylated at both its C- and N-terminus,
Figure 2. Production of recombinant tetraspanin-LELs. (a) Schematic illustration of the affinity chromatography method used for
recombinant tetraspanin LELs purification using glutathione-sepharose beads, thrombin and benzamidine-sepharose beads. (b)
Follow up of recombinant tetraspanin LELs production. The purification process was followed by Coomassie Blue staining after SDS-
PAGE separation. Lanes 1–3: Samples of 10 µL Glutathione-sepharose beads before Thrombin treatment. Lanes 5–7: 10 µL of
Glutathione-sepharose beads after treatment with Thrombin. Lanes 8–10: 20 µL of each supernatant after benzamidine-sepharose
removal of Thrombin. Red arrows indicate the final LEL biotinylated product. (c) Western blot analysis of recombinant tetraspanin
LELs. Samples were subjected to SDS-PAGE and detected by chemiluminiscence using Avidin-Biotin-HRP Complexes. Lanes 2–4:
Samples of 10 µL of AviLELAvi-GST of CD9, CD63 and CD81 coupled to Glutathione-sepharose. Lanes 5–7: Samples of 20 µL of
AviCD9LELAvi, AviCD63LELAvi and AviCD81LELAvi. Lanes 8–10 Samples of 10 µL of Glutathione-sepharose beads after Thrombin
treatment. Red arrows indicate the final LEL biotinylated product. (d) Dot blot immunodetection of recombinant tetraspanin LELs.
The final products, biotinylated CD9, CD63 and CD81 LELs, were detected by Dot-blot using ABC Peroxidase Standard Staining Kit
and monoclonal antibodies directed against CD9 (clone VJ 1/20), CD63 (TEA 3/10) and CD81 (5A6).
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Figure 3. Biotinylation efficiency of recombinant tetraspanins. (a) Samples were run on 12% SDS-PAGE and CD9 was visualised
using a specific monoclonal antibody (clone VJ 1/10) followed by a secondary goat anti-mouse antibody conjugated to HRP. Lane 1:
20 µL of non-biotinylated CD9LEL. Lane 3: 20 µL of AviCD9LELAvi. Lanes 3–4: 20 µL of AviCD9LELAvi and Streptavidin with a 3-fold
molar excess and 10-fold molar excess, respectively. Lanes 5–6: 20 µL CD9LEL and Streptavidin with a 3-fold molar excess and 10-
fold molar excess, respectively. (b) Representative images of streptavidin beads incubated with recombinant tetraspanins (lower
panels) and stained with specific mAbs and secondary antibodies. Primary antibodies used were anti-CD9 (VJ 1/20), -CD63 (TEA 3/
10) and -CD81 (5A6). Upper panels show negative controls obtained either by staining streptavidin beads not loaded with
recombinant tetraspanins with both primary and secondary antibodies (upper pannel, right) or streptavidin beads incubated
with AviCD9LELAvi recombinant tetraspanin and stained with unmatched anti-CD63 (TEA3/10) primary antibody. An optical section
acquired with a Leica TCS-SP5 confocal microscope is shown.
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binding to the tetrameric SA may help to acquire
a three-dimensional conformation that more closely
resembles that of the native tetraspanin molecule.
Indeed, binding of most anti-tetraspanin mAbs seems
to be conformation-dependent since reactivity is lost
under reducing conditions.
As a proof of concept to show that our biotinylated
recombinant proteins bind to SA and can be detected
by a variety of immunoassays, we incubated biotiny-
lated recombinant tetraspanins with SA-coated sephar-
ose beads, and stained these beads for
immunofluorescence analysis using confocal micro-
scopy. A bright specific signal could be observed on
the beads when biotinylated recombinant CD9-, CD63-
and CD81-LELs were incubated with SA-beads and
detected with their corresponding specific antibodies
(Figure 3(b), lower panels). No signal was observed
when uncoated SA-beads were stained or when
AviCD9LELAvi-coated microspheres were stained
with a primary antibody against CD63 tetraspanin
(Figure 3(b), upper panels).
Decoration of synthetic nanovesicles with
biotinylated recombinant tetraspanins
Synthetic niosomes, surface-bioconjugated to (strept)
avidin molecules, and either fluorescently labelled or
not, were incubated with the biotinylated recombinant
tetraspanin LEL peptides. Although the binding of
biotin to (strep)avidin is known to be a fast process
in solution, after immobilisation onto a surface the
kinetics of the process can be more complex and there-
fore longer incubation times may be necessary for
optimal coupling [22–24]. The coupling process was
therefore performed with an estimation of two
AviLELAvi molecules (containing two biotin molecules
each) per (strept)avidin molecule (that have four
potential biotin binding-sites available), during an
overnight incubation in a tube rotator at RT. SEC was
used to remove the unbound LEL tetraspanins. After
SEC, 20 fractions were collected from each sample and
analysed by dot blot to determine in which fractions
the decorated nanovesicles eluted. Avidin–Biotin–HRP
Complex (ABC peroxidase) would bind to both the free
biotin-binding sites on the (strept)avidin, as well as to
free biotin molecules on the tetraspanin LEL. So, to
unequivocally evaluate the presence of recombinant
tetraspanins on the niosome-containing fractions, the
dot blots were also developed using specific monoclo-
nal antibodies against each tetraspanin. Dot-blot ana-
lyses demonstrated that the decorated nanovesicles
typically eluted between fractions 6 and 10 (Figure 4
(a)). The small variability in the elution of the positive
decorated niosomes-containing fractions between dif-
ferent SEC columns may be due to the variability in
collecting the fractions from the SEC process. Dot blot
analysis, a fast and simple technique, is useful to pre-
cisely determine the nanovesicle-containing fractions
after SEC and could aid to the standardisation of this
isolation protocol.
To further determine the presence of nanovesicles in
the dot blot fractions, different SEC-fractions of CD9-
decorated niosomes were tested by NTA. Data shows
that the majority of niosomes eluted in fractions 6–8
(Figure 4(b), upper plot), thereby confirming the elu-
tion profile previously obtained by dot blot analysis.
For further analyses, decorated niosomes-containing
fractions were pooled and their size distribution and
concentration were determined by NTA. The vast
majority of decorated niosomes appeared to be
between 100 and 300 nm in size diameter, as displayed
in a representative size distribution profile of CD63-
niosomes (Figure 4(b), lower plot). Concentration of
pooled positive fractions, for both CD9 and CD63
decorated nanovesicles, was determined to be around
1 × 1011 particles/mL.
Bulk analysis of the presence of recombinant CD9
and CD63 on artificial nanovesicles was carried out by
bead-assisted FC [17] (Figure 4(c)). Here, the pooled
positive fractions of decorated niosomes were adsorbed
onto 4 µm diameter aldehyde/sulphate latex beads,
incubated with antibodies directed against CD9 or
CD63 and stained with a secondary antibody conju-
gated to Alexa Fluor 647. Bright positivity was
observed for beads that had been previously incubated
with CD9 or CD63 decorated niosomes when com-
pared to uncoated beads incubated with both primary
and secondary antibodies (Figure 4(c)).
Cryo-electron microscopy of tetraspanin-decorated
niosomes
Cryo-EM allows visualisation of samples in their native
frozen-hydrated state. Cryo-EM analyses of niosome-
samples revealed the presence of single nanovesicles
with a spherical morphology, similar to the one
observed for EVs [25]. A bilayer membrane could be
clearly appreciated at higher magnification (Figure 5(c),
lower panel). Interestingly, some lamellar and multila-
mellar structures were also visualised (Figure 5(a)).
Although rare, the presence of these multilamellar struc-
tures has been reported with various EV samples iso-
lated from biological fluids [26]. The size range of these
nanovesicles coincided with the size distribution profile
that we previously determined by NTA. The majority of
nanovesicles were between 100 and 200 nm, but a few
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Figure 4. Characterisation of tetraspanin-LEL-decorated niosomes. (a) Evaluation of SEC elution profile of decorated niosomes by
dot blot. Niosomes were coupled to biotinylated recombinant tetraspanins (CD9, CD63 and CD81LEL proteins). 1 μL of each of the
20 fractions collected after SEC was spotted onto a nitrocellulose membrane for dot-blot analysis using ABC-peroxidase and specific
monoclonal antibodies against tetraspanins CD9, CD63 and CD81 (clones VJ 1/10, TEA 3/10 and 5A6, respectively). (b) NTA-based
size determination and quantification. SEC elution profile was confirmed by quantitative NTA analyses of different SEC fractions
collected from CD9-niosome samples (upper plot). Particle concentration and mean size distribution of the pooled positive SEC
fractions were also measured. A representative size distribution profile is shown for CD63-decorated niosomes (lower graph). (c)
Bead-assisted flow cytometry of decorated niosomes. 4 µm latex beads were coated with decorated niosomes (pool of positive
fractions recovered after SEC) and labelled with primary anti-CD9 (VJ 1/20) and anti-CD63 (TEA 3/10) mAb followed by Alexa647-
labelled anti-mouse secondary antibody. Single beads were selected in the side scatter (SSC)/forward scatter (FSC) dot plot for all
samples (left panel). Alexa647-positivity was evaluated in histograms (upper panels) or in a SSC/Alexa647 dot plot (lower panels).
GeoMean values for both CD9- and CD63-decorated niosomes is indicated in the histogram plots, showing high positivity when
compared to the negative controls. Uncoated beads incubated with primary and secondary antibodies were used as negative
control (filled grey histograms). The percentage of Alexa647-positive beads is indicated in the dot plots. Experiment shown is
representative for n = 3.
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Figure 5. Cryo-Electron Microscopy of decorated niosomes. (a) Cryo-EM of CD9-Niosomes. (b) Immunogold staining of CD9 and
CD63-decorated niosomes. Antibodies used were anti-CD9 (clone VJ 1/10) on AviCD9LELAvi-decorated niosomes and anti-CD63
(clone TEA 3/18) on AviCD63LELAvi decorated niosomes. (c) Cryo-Electron Tomography analysis of a CD63-decorated niosome.
CD63-decorated niosome observed without any inclination (0°), or after tilting the sample either −57° or +43°. Magnification of
bilayer membrane structure is shown. Bars = 100 nm for all images.
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smaller (50 nm) and bigger (>200 nm) niosomes were
also detected. Thus, our bioengineered niosomes repro-
duce the heterogeneity observed with natural EVs.
To further characterise the presence of recombinant
tetraspanins on the surface of these nanovesicles in
their native state, cryo-EM was combined with immu-
nogold labelling. To this end, an incubation step with
specific antibodies directed against CD9 or CD63 was
followed by incubation with secondary antibodies con-
jugated to 15 nm gold particles. Niosomes positively
decorated with CD9 and CD63 were observed (Figure 5
(b)), although the number of gold-particles associated
to the niosome-surface was lower than expected. Due
to the small size of niosomes steric hindrance interac-
tions between antibodies (with an average size of
around 10 nm and coupled to gold nanoparticles of
15 nm) are likely to affect labelling intensity. Another
important consideration when performing immunola-
belling is the chemical fixation process, which might
alter the ultrastructure of samples [27].
Because of the perspective of view in 2-D images,
a gold nanoparticle may seem to be close to the mem-
brane of nanovesicles whereas it is actually not. Thus,
to confirm the specificity of the attachment of the gold
nanoparticles to the membrane of decorated niosomes
we performed a cryo-Electron Tomography (cryo-ET)
approach. Cryo-ET offers the possibility to observe
samples from different tilt angles, thereby avoiding
the ambiguity derived from 2-D projection images
[28]. By observing a positively stained CD63-
decorated niosome under two different tilt angles,
−57° and +43° (Figure 5(c), left and right, respectively)
we confirmed that the position of the gold nanoparti-
cles was the same as observed for the untilted CD63-
decorated niosome (Figure 5(c)).
Side by side comparison of tetraspanin-decorated
niosomes and natural EVs
So far, we have provided evidence that most techniques
employed for the characterisation of naturally occur-
ring EVs can be easily applied to tetraspanin-decorated
niosomes. To provide a side by side comparison, we
isolated EVs from conditioned media of the breast
cancer carcinoma cell line MCF7 by SEC. We mea-
sured particle concentration of these EV samples and
of niosomes decorated with CD9 peptide (both regular
and fluorescent) and we loaded serial dilutions of equal
amounts of particles on a nitrocellulose membrane that
was developed with anti-CD9 mAb in a dot-blot.
A very similar signal was obtained with natural EVs
and CD9-decorated niosomes (Figure 6(a)), whereas
fluorescent-CD9 niosomes showed a brighter CD9
signal. When matching number of EV and niosome
particles were incubated with sulphate-aldehyde latex
beads, and analysed by FC, same results were generated
(Figure 6(b)). Although different sources of naturally
occurring EVs may present different quantities of tet-
raspanins on their surface, these data show that we are
able to produce niosomes with immunoreactive tetra-
spanin regions with similar antigen-densities as those
found on naturally occurring EVs.
High-resolution flow cytometric analyses of
tetraspanin-decorated niosomes
To obtain further evidence for the presence of recom-
binant tetraspanins on the surface of niosomes at
a single particle level, and to test the suitability of
these decorated niosomes as standards for flow cyto-
metric analysis of EVs, the bioengineered niosomes
were analysed by high-resolution FC [21].
Again, a side by side comparison was performed with
CD9-decorated niosomes and natural EVs, in this case
derived from DC-conditioned media and enriched by
differential ultracentrifugation. The scatter plot of both
samples was very similar, in both fluorescence vs FSC and
SSC vs FSC dot plots (green dots for EVs and red dots for
niosomes, Figure 6(c)). For comparison, calibration poly-
styrene beads of 200 nm in diameter (dark grey) or
100 nm in diameter (light grey) were also included,
clearly highlighting a very different scattering behaviour
of this reference material (Figure 6(c)).
For high-resolution FC detection fluorescence
threshold triggering was performed [20]. To this end,
we first assessed whether the fluorescent signal derived
from the carboxyfluorescein labelled 1,2 dioleoyl-sn-
glycerol phosphoethanolamine incorporated within
the bilayer of the niosomes was enough to resolve
them above the threshold and background noise
(Figure 7(a)). Again, decorated niosomes were com-
pared in side by side measurements on the same day
with natural EVs isolated from BMDCs and stained
with PKH67, as described before [29]. The scatter
pattern observed within the fluorescein vs. rw-FSC
dot plots of CD9-niosomes resembles the pattern
found in EV samples. The dot plots displaying SSC
vs. rw-FSC also show similar scatter characteristics,
although the natural BMDC-derived EVs preparations
displayed a slightly more complex pattern than the
decorated niosomes (Figure 7(a)). These results thus
show that niosomes decorated with fluorescein-
molecules display enough fluorescence to be resolved
by fluorescence-based high-resolution flow cytometric
analysis and do not need further generic labelling to
perform fluorescence-threshold triggering.
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Figure 6. Side by side comparison of CD9-decorated niosomes and natural EVs. (a) Dot blot analysis of serial dilutions of CD9-
niosomes, CD9-fluorescent niosomes and EVs isolated by SEC from MCF7 conditioned media. Number of particles were previously
matched by NTA quantification of the three samples. (b) Bead-assisted flow cytometry of CD9-decorated niosomes and EVs isolated
from MCF7 cell culture supernatant. Upon capture, beads were incubated with anti-CD9 VJ1/20 mAb and stained with secondary
anti-mouse-Alexa 647. Negative control corresponds to beads coated with EVs in the absence of primary antibody. (c) High-
resolution flow cytometry. Dot plots of fluorescence vs. reduced wide-angle FSC (rw-FSC) or SSC vs. rw-FSC of EVs from DC
conditioned medium (green) or CD9-decorated fluorescent niosomes (red). As a reference 200 nm and 100 nm yellow-green
fluorescent (505/515) FluoSphere Carboxylate-Modified Microspheres (ThermoFisher) are plotted alongside (light and dark grey
populations, respectively).
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To confirm that nanovesicles were individually mea-
sured samples were serially diluted and acquired. Upon
dilution of fluorescein-labelled niosomes, the reduction in
event rate displayed a linear correlation and both light
scatter and fluorescent signals remained unaltered
(Figure 7(b)), thereby ruling out swarm detection [28–30].
The next step was to determine tetraspanin expres-
sion at the single niosome level. Here, niosome samples
were stained with PE-conjugated anti-tetraspanin anti-
bodies and floated into a sucrose density gradient to
separate them from unbound dye. Interestingly, when
performing density gradient floatation to separate nio-
somes from unbound antibodies, we observed that
niosomes migrated to the lowest density fraction of
the gradient (density = 1.10–1.06 g/mL) (Figure 8(c)).
Depending on the cellular origin, naturally occurring
EVs usually float to a buoyant density of 1.13–1.19 g/
mL, [30]. This difference in buoyant density likely
reflects differences in the content of the vesicles. The
difference in buoyant density of both types of nanove-
sicles could be of specific interest for spike-in experi-
ments, since niosomes could then be easily separated
from EVs by density fractionation.
Stained niosomes were thereafter analysed by high-
resolution FC using fluorescent threshold triggering.
11.8% of CD9-niosomes stained with anti-CD9-PE dis-
played specific positive signal when compared to
a CD9-niosome sample that was stained with CD81-
PE (Figure 8(a), upper right panel). For CD63-
niosomes, 11.3% of events were found positive
(Figure 8(a), lower right panel). Interestingly, when
PE-fluorescence was displayed in histograms overlaid
with their respective controls, it was clear that the
mean fluorescence intensity (MFI) of the entire popu-
lation of niosomes was shifted (Figure 8(b)). This indi-
cates that the majority of the niosomes are labelled
with tetraspanins, but not all of them could be resolved
from the background due to the low number of epi-
topes on the surface. Indeed, when compared to the
control sample there was a 1.5-fold change in the Geo-
Mean of the total decorated niosome-population for
both CD9 and CD63-niosomes. This range of positive
events over the background is comparable to that
observed when analysing antibody-stained natural
EVs [31]. These data further show that the size of the
EV imposes an enormous handicap when being
analysed by techniques relying on staining or labelling.
Smaller and brighter probes are therefore urgently
needed to achieve more quantitative results.
Single vesicle characterisation of EVs is highly chal-
lenging due to intrinsic features of the sample, includ-
ing the limited number of antigens on the surface,
which is directly limited by the size of the vesicle.
Assuming a similar antigen distribution as the one of
Figure 7. High-resolution flow cytometric analysis of decorated fluorescent niosomes. (a) Dot plots displaying fluorescence from
fluorescein or PKH67 vs. reduced wide-angle FSC (rw-FSC) and SSC vs. rw-FSC of fluorescein containing CD9-niosomes and mouse
BMDC-derived PKH67-stained EVs. (b) Serial dilutions of the CD9-niosome sample were analysed. Fluorescence vs. rw-FCS dot plots
for serial dilutions (1:20, 1:40, 1:80, 1:160 from left to right) are shown. Number of events for each dilution plot are indicated. Plots
are representative for n = 3.
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the cell of origin, it has been described that, even for
high density antigens, the number of molecules that
might be present on the surface of EVs can go down to
10 molecules [32]. For our design, we decided to use
niosomes because of their similar size range and refrac-
tive index when compared to naturally occurring EVs.
The use of particles with similar features to natural EVs
allows good comparison, also for immunodetection,
since analogous restrictions due to number of antigenic
molecules and fluorescence intensity or gold labelling
efficacy will occur. It is important to mention that
antibody-labelling strategies for single EV-detection,
such as the ones used along this manuscript for high-
resolution FC and cryo-EM, have been proved useful
for characterisation of EV-subsets. They however carry
their own limitations, like the already mentioned
effects of antigen density distribution and steric hin-
drance of antibodies. Further improvements for the
application of FC to the EV field are needed to obtain
small sized but very bright fluorochromes to overcome
these limitations. Yet, despite the fact that single-vesicle
FC is still highly challenging, the high-throughput
characterisation of small vesicles with specific markers
is one of the most powerful techniques available at this
moment. The availability of proper standards suitable
for immunolabelling would therefore greatly benefit
the advances in the optimisation of this technique.
Moreover, the EVM here described have proven to
also be suited for other isolation and characterisation
techniques currently employed in the EV field, such as
SEC, density gradients, NTA, western-blot, bead-based
FC and EM.
In addition, EV Mimetics may offer new possibilities
as drug delivery systems and vaccines [33,34]. Among
the numerous nanotechnology-based therapies, lipid-
based nanoparticles and niosomes have interesting bio-
logical properties, which include extensive biocompat-
ibility, biodegradability and the ability to entrap both
hydrophilic and hydrophobic drugs [34–36]. These
EVM may be able to increase the half-life in circulation
of the cargo, minimise toxicity and increase the ther-
apeutic effect [33–37].
Thus, here we describe for the first time a nano-
biotechnological approach to generate an EVM. These
bioengineered nanovesicles open up new possibilities for
optimisation, cross-standardisation and comparison of
EV-measurements between laboratories and techniques.
The requirement for suitable standards for EV iso-
lation, characterisation and analysis methods in the fast
developing EV-field is obvious [38], particularly since
the techniques for EV isolation and characterisation are
constantly evolving, and their applicability is
Figure 8. Immunocharacterisation of CD9 and CD63 decorated niosomes by high-resolution flow cytometry. (a) Flow cytometric dot plots
displaying CD9 and CD63 signal of fluorescein-containing CD9 and CD63-niosomes after staining with either anti-CD9-PE (clone VJ 1/20) or
anti-CD63-PE (Clone H5C6) or matched PE-conjugated negative controls (CD9-niosomes stained with anti-CD81-PE or CD63-niosomes
stained with anti-CD9-PE). Percentages of gated events are shown. (b) Histogram overlays for both CD9 and CD63-niosomes and their
respective negative controls (darker histograms). GeoMean Fluorescence Intensities of the total populations are indicated. (c) Schematic
representation of density gradient flotation performed on antibody-labelled decorated niosomes. Bar graph displaying the fractionation
profile of CD9 and CD63-niosomes after sucrose density gradient flotation. The number of events in each fraction is determined using
quantitative time-based flow cytometric analysis (number of fluorescein-positive events in 30 s).
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exponentially increasing. Appealing features such as
size distribution, morphology and particle concentra-
tion make these bioengineered nanovesicles suitable for
different EV isolation and detection procedures. We
have chosen to initiate the development of EVMs
with tetraspanin LELs, but the technology that we
describe here is adaptable to the incorporation of dif-
ferent protein markers. By taking advantage of the
high-affinity interaction between (strept)avidin and
biotin molecules it is possible to perform surface-
decoration with any potential protein of interest,
which make these nanovesicles tuneable. In addition,
they can be generically stained with fluorescent dyes.
Since the here-described surface-decorated niosomes
display similar biophysical properties as naturally
occurring EVs, and are suited for staining with anti-
bodies directed against the most widely used tetraspa-
nins within the EV-field, they can be powerful intrinsic
controls for EV characterisation platforms like NTA,
Electron Microscopy and FC. Additionally, they are
detectable by different bulk-based analysis techniques,
such as dot blot, western blot and bead-based FC.
Moreover, because of their specific density properties,
they could be easily adapted as spike-ins for robust
assessment in all these techniques.
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